Co-Diagnostics, Inc. (NASDAQ: CODX) shares shot up on Tuesday after the company announced that it has entered into an agreement with Arches Research to expand Arches’ COVID-19 testing services using Co-Diagnostics’ test kit.
Worth noting is that Arches Research is certified under the Clinical Laboratory Improvement Amendments (CLIA) and is a subsidiary of PolarityTE, Inc, (NASDAQ: PTE).
The agreement centers around Co-Diagnostics’ Logix Smart COVID-19 test kit. Arches Research began using Co-Diagnostics’ tests for its customers earlier this year. The announcement follows news last week of additional, independent third-party validations supporting the test kit’s performance.
The Logix Smart test kit is authorized to be used for the diagnosis of SARS-CoV-2, the virus that causes COVID-19, in the United States and many other countries.
Arches received a CLIA certificate of registration at the end of April and began testing for COVID-19 shortly after. The CLIA is regulated by the Centers for Medicare & Medicaid Services (CMS) with a primary goal to ensure quality laboratory testing.
Excluding Tuesday’s move, Co-Diagnostics’ stock is up over 820% year to date. In the past 52-weeks, the stock is up over 655%.
Co-Diagnostics stock was last seen up about 40% at $11.52, with a 52-week range of $0.85 to $30.99. The consensus analyst price target is $35.33.
PolarityTE was recently trading up about 10% at $1.15, with a 52-week range of $0.78 to $5.08. Analysts have a consensus analyst price target of $3.33 for the stock.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
